Printed as of 4/16/2024

Disclosures

Personal Commercial (1)

 Company Name
 Relationship Category
 Compensation Level
 Topic Area(s)

 Self

 Boehringer Ingelheim Pharmaceuticals, Inc
 Consultant Fees/Honoraria
 Significant (>= \$5,000)

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (1)

Trial Name	Trial Sponsor	Trial Funding Source
ADAPT RESPONSE CLINICAL TRIAL	MEDTRONIC	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (6)

Year	Case Title	Represented	Description	Compensation
Self				
2019	Pradaxa	Defendant	Expert witness for Boehringer Ingelheim in Pradaxa litigation	Significant (>= \$5,000)
2018	Pradaxa	Defendant	Expert witness for Boehringer Ingelheim in Pradaxa litigation	Significant (>= \$5,000)
2018	pacemaker implant in patient with vasospastic angina	Defendant		Modest (< \$5,000)
2017	angioedema on ACE inhibitor	Defendant		Significant (>= \$5,000)
2017	post TAVR pacemaker complication	Defendant		Modest (< \$5,000)
2011	anticoagulation post cardioversion	Defendant	provided initial consultation	Modest (< \$5,000)
				t Commencial Francisco Comment to Trial Name

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 7/13/2019

 $\textit{URL for full agreement: http://disclosures.acc.org/Public/Definition/Certified Education Attest at ion Agreement agreement$

Confidentiality, Disclosure and Assignment Agreement | Signed on 7/13/2019

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 7/13/2019

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/20/2020

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.